XML 94 R69.htm IDEA: XBRL DOCUMENT v3.20.4
Goodwill and Other Intangibles (Narrative) (Details) - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Feb. 15, 2019
Finite-lived intangible assets:        
Goodwill, impairment loss $ 0 $ 0 $ 0  
Remaining amortization period 15 years      
Loxo Oncology, Inc.        
Finite-lived intangible assets:        
Acquired IPR&D       $ 4,670,000,000.0
Selpercatinib (LOXO-292) | Loxo Oncology, Inc.        
Finite-lived intangible assets:        
Acquired IPR&D       $ 4,600,000,000
Minimum        
Finite-lived intangible assets:        
Finite-lived intangible asset, useful life 3 years      
Maximum        
Finite-lived intangible assets:        
Finite-lived intangible asset, useful life 20 years